Immunotherapy with allotumour mRNA-transfected dendritic cells in androgen-resistant prostate cancer patients

Here, we present results from a clinical trial employing a new vaccination method using dendritic cells (DCs) transfected with mRNA from allogeneic prostate cancer cell lines (DU145, LNCaP and PC-3). In all, 20 patients were enrolled and 19 have completed vaccination. Each patient received at least...

Descripción completa

Detalles Bibliográficos
Autores principales: Mu, L J, Kyte, J A, Kvalheim, G, Aamdal, S, Dueland, S, Hauser, M, Hammerstad, H, Waehre, H, Raabe, N, Gaudernack, G
Formato: Texto
Lenguaje:English
Publicado: Nature Publishing Group 2005
Materias:
Clinical Study
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2361645/
https://www.ncbi.nlm.nih.gov/pubmed/16136047
http://dx.doi.org/10.1038/sj.bjc.6602761

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2361645/
https://www.ncbi.nlm.nih.gov/pubmed/16136047
http://dx.doi.org/10.1038/sj.bjc.6602761

Ejemplares similares